title: Metabolic mapping of the effects of the antidepressant fluoxetine on the brains of congenitally helpless rats.
abstract: Antidepressants require adaptive brain changes before efficacy is achieved, and they may impact the affectively disordered brain differently than the normal brain. We previously demonstrated metabolic disturbances in limbic and cortical regions of the congenitally helpless rat, a model of susceptibility to affective disorder, and we wished to test whether administration of fluoxetine would normalize these metabolic differences. Fluoxetine was chosen because it has become a first-line drug for the treatment of affective disorders. We hypothesized that fluoxetine antidepressant effects may be mediated by decreasing metabolism in the habenula and increasing metabolism in the ventral tegmental area. We measured the effects of fluoxetine on forced swim behavior and regional brain cytochrome oxidase activity in congenitally helpless rats treated for 2 weeks with fluoxetine (5mg/kg, i.p., daily). Fluoxetine reduced immobility in the forced swim test as anticipated, but congenitally helpless rats responded in an atypical manner, i.e., increasing climbing without affecting swimming. As hypothesized, fluoxetine reduced metabolism in the habenula and increased metabolism in the ventral tegmental area. In addition, fluoxetine reduced the metabolism of the hippocampal dentate gyrus and dorsomedial prefrontal cortex. This study provided the first detailed mapping of the regional brain effects of an antidepressant drug in congenitally helpless rats. All of the effects were consistent with previous studies that have metabolically mapped the effects of serotonergic antidepressants in the normal rat brain, and were in the predicted direction of metabolic normalization of the congenitally helpless rat for all affected brain regions except the prefrontal cortex.
authors.affiliation: Department of Psychology and Pharmacology, University of Texas at Austin, TX 78712, USA.
authors.forename: Jason
authors.initials: J
authors.lastname: Shumake
authors.forename: Rene A
authors.initials: RA
authors.lastname: Colorado
authors.forename: Douglas W
authors.initials: DW
authors.lastname: Barrett
authors.forename: F
authors.initials: F
authors.lastname: Gonzalez-Lima
mesh_terms: D000818:Animals; D018687:Antidepressive Agents, Second-Generation / Q000494:pharmacology; D001921:Brain / Q000187:drug effects* / Q000378:metabolism* / Q000503:physiopathology; D001931:Brain Mapping / Q000379:methods; D003866:Depressive Disorder / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism*; D004195:Disease Models, Animal; D003576:Electron Transport Complex IV / Q000378:metabolism; D004734:Energy Metabolism / Q000187:drug effects* / Q000502:physiology; D005473:Fluoxetine / Q000494:pharmacology*; D008297:Male; D051381:Rats; D011919:Rats, Inbred Strains; D017367:Selective Serotonin Reuptake Inhibitors / Q000494:pharmacology; D013550:Swimming / Q000523:psychology
chemical_list: D018687:Antidepressive Agents, Second-Generation; D003576:Electron Transport Complex IV; D005473:Fluoxetine; D017367:Selective Serotonin Reuptake Inhibitors
references.citation: Brain Res. 1980 Jul 21;194(1):117-24
references.pmid: 7378832
references.citation: Biol Psychiatry. 2000 Oct 15;48(8):830-43
references.pmid: 11063978
references.citation: Biol Psychiatry. 2009 Sep 1;66(5):441-50
references.pmid: 19539268
references.citation: J Neurochem. 1979 Jan;32(1):15-22
references.pmid: 759566
references.citation: Behav Brain Res. 2004 Apr 2;150(1-2):217-21
references.pmid: 15033295
references.citation: Am J Psychiatry. 1999 May;156(5):675-82
references.pmid: 10327898
references.citation: Pharmacol Biochem Behav. 2004 May;78(1):165-9
references.pmid: 15159146
references.citation: Biol Psychiatry. 1997 Jan 1;41(1):15-22
references.pmid: 8988791
references.citation: Aust N Z J Psychiatry. 1999 Oct;33(5):642-9
references.pmid: 10544987
references.citation: J Neurosci. 1981 Mar;1(3):285-91
references.pmid: 7264720
references.citation: Psychopharmacology (Berl). 2002 Apr;160(4):353-61
references.pmid: 11919662
references.citation: J Neurosci. 1988 Jun;8(6):1951-61
references.pmid: 3385484
references.citation: J Neurosci. 2010 Apr 28;30(17):5876-83
references.pmid: 20427648
references.citation: Brain Res. 2004 Dec 31;1030(2):267-76
references.pmid: 15571675
references.citation: Neuroreport. 2000 Nov 27;11(17):3793-8
references.pmid: 11117493
references.citation: Psychopharmacol Bull. 1985;21(3):443-6
references.pmid: 2994157
references.citation: Psychiatry Res. 1999 Oct 11;91(3):127-39
references.pmid: 10641577
references.citation: Behav Brain Res. 2005 Nov 7;164(2):222-30
references.pmid: 16095730
references.citation: J Neurochem. 1984 Sep;43(3):724-32
references.pmid: 6540296
references.citation: J Clin Psychiatry. 1999 Sep;60(9):574-9
references.pmid: 10520974
references.citation: Synapse. 2007 Feb;61(2):72-7
references.pmid: 17117425
references.citation: Synapse. 2004 Apr;52(1):73-5
references.pmid: 14755634
references.citation: Br J Pharmacol. 1995 Sep;116(2):1923-31
references.pmid: 8528581
references.citation: Brain Res Mol Brain Res. 1992 Jun;14(1-2):94-100
references.pmid: 1353857
references.citation: Behav Cogn Neurosci Rev. 2003 Sep;2(3):198-221
references.pmid: 15006293
references.citation: Arch Gen Psychiatry. 2009 Aug;66(8):848-56
references.pmid: 19652124
references.citation: Pharmacol Biochem Behav. 2008 May;89(3):456-62
references.pmid: 18313125
references.citation: Neuroscience. 1994 Nov;63(2):559-78
references.pmid: 7891865
references.citation: Neuroscience. 2002;114(2):373-7
references.pmid: 12204206
references.citation: Pharmacol Biochem Behav. 1982 Oct;17(4):841-5
references.pmid: 7178192
references.citation: Psychopharmacology (Berl). 2009 Dec;207(2):315-23
references.pmid: 19760282
references.citation: Psychopharmacology (Berl). 1995 Sep;121(1):66-72
references.pmid: 8539342
references.citation: Nature. 1977 Apr 21;266(5604):730-2
references.pmid: 559941
references.citation: Biol Psychiatry. 2001 Aug 15;50(4):231-7
references.pmid: 11522256
references.citation: Am J Psychiatry. 1996 Feb;153(2):151-62
references.pmid: 8561194
references.citation: Brain Res. 2000 Jan 31;854(1-2):35-41
references.pmid: 10784104
references.citation: Brain Res. 2003 Feb 14;963(1-2):274-81
references.pmid: 12560133
references.citation: Biol Psychiatry. 1999 Nov 1;46(9):1181-91
references.pmid: 10560024
references.citation: Brain Res Brain Res Rev. 2005 Feb;48(1):1-15
references.pmid: 15708625
references.citation: Prog Neuropsychopharmacol Biol Psychiatry. 1982;6(3):277-95
references.pmid: 6128769
references.citation: Neurosci Lett. 2001 Sep 21;311(1):45-8
references.pmid: 11585564
references.citation: Neuroimage. 1999 Aug;10(2):163-72
references.pmid: 10417248
references.citation: Neuropsychopharmacology. 1999 Aug;21(2 Suppl):91S-98S
references.pmid: 10432494
references.citation: Behav Brain Res. 2010 May 1;209(1):183-6
references.pmid: 20122969